<DOC>
	<DOC>NCT01961232</DOC>
	<brief_summary>The investigators are testing whether the addition of Pulmonary Hypertension-related biomarkers, measured across the pulmonary circulation, to the standard hemodynamic evaluation for Pulmonary Hypertension will lead to more informed choices of Pulmonary Hypertension therapy and improved patient outcomes.</brief_summary>
	<brief_title>Trans-pulmonary Biomarkers in Pulmonary Hypertension</brief_title>
	<detailed_description>Eligible participants with known or suspected Pulmonary Hypertension undergoing a clinically indicated right heart catheterization may be enrolled. Clinical data and blood samples will be analyzed.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Age ≥ 18 years old Undergoing RHC for PH evaluation Anemia defined as Hgb &lt; 10 g/dL and HCT &lt; 30 Pregnancy at the time of RHC (as assessed by urine or serum pregnancy test on the day of the procedure) Left ventricular ejection fraction ≤ 40% Atrial fibrillation at the time of RHC (as defined by telemetry monitoring or EKG on the day of the procedure) IPF, CTEPH, COPD/OSA as the dominant etiology of PH Patient is currently taking PH medication or longacting nitrates at the time of their RHC.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pulmonary Hypertension</keyword>
	<keyword>biomarker</keyword>
	<keyword>cardiac</keyword>
	<keyword>circulation</keyword>
	<keyword>heart disease</keyword>
	<keyword>lung disease</keyword>
</DOC>